GLP1R and generalized anxiety disorder: Data were collected using a questionnaire developed by the research team, in addition to the Arabic versions of the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7).<h4>Results</h4>A total of 235 participants were included, of whom 48.5% used GLP-1 receptor agonists for both glycemic control and weight loss.